Thoracic radiation therapy and concomitant low-dose daily paclitaxel in non-small cell lung cancer: A phase I study

Carlo Gobitti, Giovanni Franchin, Emilio Minatel, Marco Gigante, Barbara Basso, Laurentiu Bujor, Mauro G. Trovò

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The primary objective of the current study was to determine the maximum tolerated dose of paclitaxel (PTX) that could be added daily to radiation therapy (RT) in patients with non-small cell lung cancer (NSCLC). The secondary objective was to achieve a plasma concentration of PTX estimated to exert a radiosensitizing effect. Eighteen patients with locally advanced NSCLC were treated. 60 Gy of RT were given in 2 Gy fractions, 5 days per week. A daily dose of PTX was delivered by 4-h i.v. infusion before RT. The initial dose level of PTX was 9 mg/m2/day, escalated by 1 mg at each additional patient triplet. Two out of 6 patients experienced acute dose limiting toxicity (DLT) at the 12 mg/m2/day PTX dose level. PTX continuously greater than 10 nM, the estimated radiosensitizing condition, was achieved at the PTX dose level of 12 mg/m2/ day. PTX at doses up to 11 mg/m2/day may be safely added to a conventional conformal RT course. Both DLT and the estimated radiosensitizing plasma exposure to PTX were encountered at the 12 mg/m 2/day dose level.

Original languageEnglish
Pages (from-to)1647-1653
Number of pages7
JournalOncology Reports
Volume14
Issue number6
Publication statusPublished - Dec 2005

Fingerprint

Paclitaxel
Non-Small Cell Lung Carcinoma
Radiotherapy
Thorax
Radiation-Sensitizing Agents
Radiation Dosage
Maximum Tolerated Dose

Keywords

  • Non-small cell lung cancer
  • Paclitaxel
  • Radiation sensitizing agents
  • Radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Thoracic radiation therapy and concomitant low-dose daily paclitaxel in non-small cell lung cancer : A phase I study. / Gobitti, Carlo; Franchin, Giovanni; Minatel, Emilio; Gigante, Marco; Basso, Barbara; Bujor, Laurentiu; Trovò, Mauro G.

In: Oncology Reports, Vol. 14, No. 6, 12.2005, p. 1647-1653.

Research output: Contribution to journalArticle

Gobitti, Carlo ; Franchin, Giovanni ; Minatel, Emilio ; Gigante, Marco ; Basso, Barbara ; Bujor, Laurentiu ; Trovò, Mauro G. / Thoracic radiation therapy and concomitant low-dose daily paclitaxel in non-small cell lung cancer : A phase I study. In: Oncology Reports. 2005 ; Vol. 14, No. 6. pp. 1647-1653.
@article{2c6d7459a5d94c29904c91e047bfe26d,
title = "Thoracic radiation therapy and concomitant low-dose daily paclitaxel in non-small cell lung cancer: A phase I study",
abstract = "The primary objective of the current study was to determine the maximum tolerated dose of paclitaxel (PTX) that could be added daily to radiation therapy (RT) in patients with non-small cell lung cancer (NSCLC). The secondary objective was to achieve a plasma concentration of PTX estimated to exert a radiosensitizing effect. Eighteen patients with locally advanced NSCLC were treated. 60 Gy of RT were given in 2 Gy fractions, 5 days per week. A daily dose of PTX was delivered by 4-h i.v. infusion before RT. The initial dose level of PTX was 9 mg/m2/day, escalated by 1 mg at each additional patient triplet. Two out of 6 patients experienced acute dose limiting toxicity (DLT) at the 12 mg/m2/day PTX dose level. PTX continuously greater than 10 nM, the estimated radiosensitizing condition, was achieved at the PTX dose level of 12 mg/m2/ day. PTX at doses up to 11 mg/m2/day may be safely added to a conventional conformal RT course. Both DLT and the estimated radiosensitizing plasma exposure to PTX were encountered at the 12 mg/m 2/day dose level.",
keywords = "Non-small cell lung cancer, Paclitaxel, Radiation sensitizing agents, Radiation therapy",
author = "Carlo Gobitti and Giovanni Franchin and Emilio Minatel and Marco Gigante and Barbara Basso and Laurentiu Bujor and Trov{\`o}, {Mauro G.}",
year = "2005",
month = "12",
language = "English",
volume = "14",
pages = "1647--1653",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Thoracic radiation therapy and concomitant low-dose daily paclitaxel in non-small cell lung cancer

T2 - A phase I study

AU - Gobitti, Carlo

AU - Franchin, Giovanni

AU - Minatel, Emilio

AU - Gigante, Marco

AU - Basso, Barbara

AU - Bujor, Laurentiu

AU - Trovò, Mauro G.

PY - 2005/12

Y1 - 2005/12

N2 - The primary objective of the current study was to determine the maximum tolerated dose of paclitaxel (PTX) that could be added daily to radiation therapy (RT) in patients with non-small cell lung cancer (NSCLC). The secondary objective was to achieve a plasma concentration of PTX estimated to exert a radiosensitizing effect. Eighteen patients with locally advanced NSCLC were treated. 60 Gy of RT were given in 2 Gy fractions, 5 days per week. A daily dose of PTX was delivered by 4-h i.v. infusion before RT. The initial dose level of PTX was 9 mg/m2/day, escalated by 1 mg at each additional patient triplet. Two out of 6 patients experienced acute dose limiting toxicity (DLT) at the 12 mg/m2/day PTX dose level. PTX continuously greater than 10 nM, the estimated radiosensitizing condition, was achieved at the PTX dose level of 12 mg/m2/ day. PTX at doses up to 11 mg/m2/day may be safely added to a conventional conformal RT course. Both DLT and the estimated radiosensitizing plasma exposure to PTX were encountered at the 12 mg/m 2/day dose level.

AB - The primary objective of the current study was to determine the maximum tolerated dose of paclitaxel (PTX) that could be added daily to radiation therapy (RT) in patients with non-small cell lung cancer (NSCLC). The secondary objective was to achieve a plasma concentration of PTX estimated to exert a radiosensitizing effect. Eighteen patients with locally advanced NSCLC were treated. 60 Gy of RT were given in 2 Gy fractions, 5 days per week. A daily dose of PTX was delivered by 4-h i.v. infusion before RT. The initial dose level of PTX was 9 mg/m2/day, escalated by 1 mg at each additional patient triplet. Two out of 6 patients experienced acute dose limiting toxicity (DLT) at the 12 mg/m2/day PTX dose level. PTX continuously greater than 10 nM, the estimated radiosensitizing condition, was achieved at the PTX dose level of 12 mg/m2/ day. PTX at doses up to 11 mg/m2/day may be safely added to a conventional conformal RT course. Both DLT and the estimated radiosensitizing plasma exposure to PTX were encountered at the 12 mg/m 2/day dose level.

KW - Non-small cell lung cancer

KW - Paclitaxel

KW - Radiation sensitizing agents

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=33644701840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644701840&partnerID=8YFLogxK

M3 - Article

C2 - 16273271

AN - SCOPUS:33644701840

VL - 14

SP - 1647

EP - 1653

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 6

ER -